Compare Monster Beverage Corp (MNST) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Revvity Inc — how do they compare? Monster Beverage Corp trades at $45.66 (market cap $89.20B), while Revvity Inc trades at $116.32 (market cap $12.91B). The key difference: Monster Beverage Corp is far larger — about 6.9× Revvity Inc's market cap, and Revvity Inc pays a 0.24% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| MNST | RVTY | |
|---|---|---|
Market Cap | $89.20B | $12.91B |
Sector | Consumer Staples | Technology |
52-Week High | $49.97 | $117.75 |
52-Week Low | $30.86 | $82.26 |
Enterprise Value | $87.49B | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $45.53, down 0.35% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $8.29B and net income of $1.91B, maintaining robust profit margins above 23%. Recent Q2 2026 results exceeded expectations with $0.60 EPS versus $0.59 expected, driven by international growth. The stock completed a 2-for-1 split on August 11, 2026.
MNST presents a mixed outlook with strong earnings momentum and international expansion offset by premium valuation concerns. The stock trades at 42.16x P/E, above sector averages, while analyst consensus targets $51.14 suggest 12% upside. Key risks include competitive pressures in energy drinks and valuation sensitivity to growth sustainability.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
